Fidelity Investments’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.28M | Buy |
748,974
+75,010
| +11% | +$224K | ﹤0.01% | 2706 |
|
|
2026
Q1 | $2.08M | Buy |
673,964
+109,871
| +19% | +$467K | ﹤0.01% | 2631 |
|
|
2025
Q4 | $2.04M | Buy |
564,093
+118,956
| +27% | +$519K | ﹤0.01% | 2611 |
|
|
2025
Q3 | $1.68M | Buy |
445,137
+43,294
| +11% | +$167K | ﹤0.01% | 2606 |
|
|
2025
Q2 | $1.56M | Buy |
401,843
+381,040
| +1,832% | +$2.06M | ﹤0.01% | 2573 |
|
|
2025
Q1 | $104K | Sell |
20,803
-35,936
| -63% | -$228K | ﹤0.01% | 3538 |
|
|
2024
Q4 | $409K | Buy |
56,739
+5,679
| +11% | +$43.4K | ﹤0.01% | 3002 |
|
|
2024
Q3 | $314K | Buy |
51,060
+43,166
| +547% | +$292K | ﹤0.01% | 3037 |
|
|
2024
Q2 | $52.5K | Sell |
7,894
-3,218
| -29% | -$23.7K | ﹤0.01% | 3597 |
|
|
2024
Q1 | $113K | Sell |
11,112
-50,994
| -82% | -$519K | ﹤0.01% | 3232 |
|
|
2023
Q4 | $699K | Sell |
62,106
-4,941
| -7% | -$20.6K | ﹤0.01% | 2577 |
|
|
2023
Q3 | $174K | Buy |
67,047
+66,263
| +8,452% | +$190K | ﹤0.01% | 2931 |
|
|
2023
Q2 | $2.77K | Sell |
784
-1,179
| -60% | -$5.29K | ﹤0.01% | 4513 |
|
|
2023
Q1 | $8.28K | Sell |
1,963
-324
| -14% | -$3.85K | ﹤0.01% | 4205 |
|
|
2022
Q4 | $37.6K | Sell |
2,287
-38,426
| -94% | -$432K | ﹤0.01% | 3534 |
|
|
2022
Q3 | $520K | Buy |
40,713
+39,920
| +5,034% | +$589K | ﹤0.01% | 2769 |
|
|
2022
Q2 | $9K | Buy |
793
+285
| +56% | +$1.76K | ﹤0.01% | 4127 |
|
|
2022
Q1 | $3K | Buy |
+508
| New | +$3.74K | ﹤0.01% | 4542 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 4283 |
|
|
2021
Q2 | $0 | Buy |
+1
| New | +$14 | ﹤0.01% | 4188 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | – | – | 3945 |
|
|
2020
Q4 | $0 | Buy |
+1
| New | +$12 | ﹤0.01% | 3795 |
|
|
2020
Q3 | – | Sell |
-1,600
| Closed | -$17K | – | 3642 |
|
|
2020
Q2 | $17K | Buy |
+1,600
| New | +$8.79K | ﹤0.01% | 3016 |
|
|
2019
Q4 | – | Sell |
-1
| Closed | – | – | 3749 |
|
|
2019
Q3 | $0 | Buy |
+1
| New | +$2 | ﹤0.01% | 3743 |
|
|
2015
Q4 | – | Sell |
-1,081
| Closed | -$431K | – | 2730 |
|
|
2015
Q3 | $431K | Buy |
+1,081
| New | +$512K | ﹤0.01% | 2609 |
|
|
2014
Q1 | – | Sell |
-368
| Closed | -$205K | – | 2656 |
|
|
2013
Q4 | $205K | Buy |
+368
| New | +$220K | ﹤0.01% | 2584 |
|
|
2013
Q3 | – | Sell |
-389
| Closed | -$186K | – | 2610 |
|
|
2013
Q2 | $186K | Buy |
+389
| New | +$193K | ﹤0.01% | 2556 |
|
Other funds holding ALT
DTC
TCM
RCM
Fidelity Investments's ALT Position: Q2 2026 in Review
Fidelity Investments increased its Altimmune (ALT) stake by 11% in Q2 2026, buying an estimated $224K and bringing the position to 748,974 shares worth $2.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2706.
Fidelity Investments first reported a position in ALT in Q2 2013 and has held it in 25 quarters since. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.
- Fidelity Investments held 748,974 shares of Altimmune worth $2.28M as of Q2 2026.
- Fidelity Investments bought 75,010 Altimmune shares in Q2 2026, an estimated $224K.
- Altimmune made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2706 holding.
- Fidelity Investments first reported a position in Altimmune in Q2 2013 and has held it in 25 quarters since.
- 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.